Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nidogen-1 (NID1) is a highly conserved sulfated glycoprotein and critical extracellular matrix component of basement membranes in nearly all tissues[1][3][4][9]. It serves as a structural linker that tightly binds laminin, collagen IV, perlecan, and fibronectin, bridging the networks formed by these molecules to maintain basement membrane stability and integrity[1][4][9]. Nidogen-1 supports tissue architecture, influences cell adhesion and migration, and regulates developmental processes and the stem cell niche[3][4]. Mutations or dysregulation of NID1 are implicated in developmental syndromes such as Dandy–Walker malformation and have been associated with tumor progression, particularly in cancers of epithelial origin[1][4][7][9]. While essential for basement membrane structure and function, there are currently no known drugs that directly modulate nidogen-1, nor is it a typical therapeutic target in clinical pharmacology.
Not applicable; currently, there are no drugs known to act directly or specifically on nidogen-1
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nidogen-1 (NID1).